Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling

Executive Summary

Only 14 of the 170 brand-generic patent suit settlements in US during FY 2015 potentially involve payments to delay generics; number drops to 5 when payments for litigation fees are excluded.

You may also be interested in...



Teva Strikes Two Settlements Over ‘Pay-For-Delay’ Agreements

A California Court has secured four major settlements worth $70m with pharmaceutical companies over allegations of entering into collusive pay-for-delay agreements, including two with Teva.

FTC Focus On Pay-For-Delay Deals Continues; Endo Agrees To 10-Year Abstention

In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.

Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals

$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB002091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel